Showing results (51-60 of 135) with videos related to
Sort By:
Pageof 14
Clinical Neuropharmacology|June 1, 1996
Intranasal apomorphine rescue therapy for parkinsonian "off" periodsR B Dewey, D M Maraganore, J E Ahlskog, et al.Journal of Neurology, Neurosurgery, and Psychiatry|February 1, 1995
Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteriaS J Collins, J E Ahlskog, J E Parisi, et al.Movement Disorders : Official Journal of the Movement Disorder Society|January 1, 1992
Movement disorders as sequelae of central pontine myelinolysis: report of three casesD M Maraganore, W N Folger, J W Swanson, et al.Mayo Clinic Proceedings|April 1, 1991
Selective peripheral denervation for torticollis: preliminary resultsD H Davis, J E Ahlskog, W J Litchy, et al.Movement Disorders : Official Journal of the Movement Disorder Society|October 2, 1998
A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's diseaseR B Dewey, D M Maraganore, J E Ahlskog, et al.Movement Disorders : Official Journal of the Movement Disorder Society|June 5, 1998
Cortical myoclonus in levodopa-responsive parkinsonismJ N Caviness, C H Adler, S Newman, et al.Neurology|May 1, 1990
An examination of male-female differences in progression and mortality of Parkinson's diseaseS G Diamond, C H Markham, M M Hoehn, et al.Annals of Neurology|July 1, 1987
Multi-center study of Parkinson mortality with early versus later dopa treatmentS G Diamond, C H Markham, M M Hoehn, et al.European Journal of Neurology|September 22, 2006
Neuropsychological profiles of manganese neurotoxicityK J Klos, M Chandler, N Kumar, et al.Neurology|November 14, 2001
Lewy bodies are not increased in progressive supranuclear palsy compared with normal controlsY Tsuboi, J E Ahlskog, H Apaydin, et al.Pageof 14